Average Co-Inventor Count = 1.33
ph-index = 3
The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.
Company Filing History:
1. Institut National De La Sante Et De La Recherche Medicale (6 from 1,743 patents)
2. Université Paul Sabatier (toulouse Iii) (3 from 124 patents)
3. Pfizer Corporation (2 from 4,455 patents)
4. Université Cote D'azur (2 from 14 patents)
5. Université Nice Sophia Antipolis (1 from 18 patents)
6. Therachon Sas (1 from 1 patent)
7. Centre National De La Recherche Scientifique (5,076 patents)
8. Inserm (institut National De La Sante Et De La Recherche Medicale) (37 patents)
9. Inserm (0 patent)
6 patents:
1. 11814654 - Soluble fibroblast growth factor receptor 3 (FGR3) polypeptide for use in the prevention or treatment of skeletal growth retardation disorders
2. 11702642 - Soluble fibroblast growth factor receptor 3 (FGR3) polypeptide for use in the prevention or treatment of skeletal growth retardation disorders
3. 11697678 - Soluble fibroblast growth factor receptor 3 (SFGFR3) polypeptides and uses thereof
4. 11021528 - Soluble fibroblast growth factor receptor 3 (SFGFR3) polypeptides and uses thereof
5. 10724014 - Soluble fibroblast growth factor receptor 3 (FGR3) polypeptide for use in the prevention or treatment of skeletal growth retardation disorders
6. 10294289 - Soluble fibroblast growth factor receptor 3 (SFGFR3) polypeptides and uses thereof